Biomarin Pharmaceutical - Registered Shares Return on Equity

The latest ROE for BMRN is 1.15%. That is below the Healthcare sector average of 11.15%. Investors often review this figure alongside Biomarin Pharmaceutical - Registered Shares's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, BMRN currently prints 1.15% for ROE, while the sector average sits near 11.15%. That is roughly 89.7% below the sector mean. Large gaps often invite a closer look at Biomarin Pharmaceutical - Registered Shares's growth, margins, and balance sheet.

Return on Equity shows how effectively Biomarin Pharmaceutical - Registered Shares converts resources into returns. At 1.15%, BMRN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BMRN's ROE (1.15%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Biomarin Pharmaceutical - Registered Shares's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.